Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week 16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks, excluding a screening period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tildrakizumab 100 mg | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Injections of tildrakizumab | Drug | given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in Quality of Life Measured by Change From Baseline in Psychological General Well-Being Scale | The Psychological General Well-Being scale is a self-administered validated psychometric instrument that measures a person's emotional well-being. It is specifically designed to be suitable for assessing psychological well being in the general medical population as opposed to a psychiatric population. The 22 questions of the PGWB can be further divided into 6 domains: anxiety, depressed mood, positive well being, self-control, general health, and vitality. The PGWB is graded on a Likert scale, which is commonly used in psychometric questionnaires where the answers range from strongly agree to strongly disagree with gradations in between. Total scores range from 0 to 110, with higher scores indicating better psychological well being. This instrument has been validated and used in many countries on large samples of the general population and on various subsets of medical patients. The values reported are change in score from baseline. | baseline, week 28 and week 52 |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in Quality of Life Measured by Change From Baseline in Psychological General Well-Being Scale Over Time | The Psychological General Well-Being scale is a self-administered validated psychometric instrument that measures a person's emotional well-being. It is specifically designed to be suitable for assessing psychological well being in the general medical population as opposed to a psychiatric population. The 22 questions of the PGWB can be further divided into 6 domains: anxiety, depressed mood, positive well being, self-control, general health, and vitality. The PGWB is graded on a Likert scale, which is commonly used in psychometric questionnaires where the answers range from strongly agree to strongly disagree with gradations in between. Total scores range from 0 to 110, with higher scores indicating better psychological well being. This instrument has been validated and used in many countries on large samples of the general population and on various subsets of medical patients. The values reported are change in score from baseline. |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-emergent AEs | The reported values are entered in the 'Other Adverse events' section | baseline, weeks 4, 8, 12, 16, 28, 40, 52,,64 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Therapeutics Clinical Research | San Diego | California | 92123 | United States | ||
| Site 02 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38575729 | Derived | Bhutani T, Koo J, Heim J, Bhatia N, Mathew J, Ferro T, Vasquez JG. Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatol Ther (Heidelb). 2024 Apr;14(4):1019-1025. doi: 10.1007/s13555-024-01131-1. Epub 2024 Apr 4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Tildrakizumab 100 mg | Injections of tildrakizumab: given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52 |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Tildrakizumab 100 mg | Injections of tildrakizumab: given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Improvement in Quality of Life Measured by Change From Baseline in Psychological General Well-Being Scale | The Psychological General Well-Being scale is a self-administered validated psychometric instrument that measures a person's emotional well-being. It is specifically designed to be suitable for assessing psychological well being in the general medical population as opposed to a psychiatric population. The 22 questions of the PGWB can be further divided into 6 domains: anxiety, depressed mood, positive well being, self-control, general health, and vitality. The PGWB is graded on a Likert scale, which is commonly used in psychometric questionnaires where the answers range from strongly agree to strongly disagree with gradations in between. Total scores range from 0 to 110, with higher scores indicating better psychological well being. This instrument has been validated and used in many countries on large samples of the general population and on various subsets of medical patients. The values reported are change in score from baseline. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | baseline, week 28 and week 52 |
Week 64
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Tildrakizumab 100 mg | Injections of tildrakizumab: given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| COVID-19 pneumonia | Infections and infestations | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Head-Clinical Development | Sun Pharmaceutical Industries Limited | 2266455645 | 5689 | clinical.trials@sunpharma.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jan 2, 2020 | Oct 31, 2022 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Feb 24, 2021 | Oct 31, 2022 | SAP_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| baseline, weeks 4, 8, 12, 16, 40, 64 |
| Improvement in Quality of Life Measured by Change From Baseline in Dermatology Life Quality Index Over Time | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life | week 64 |
| Proportion of Subjects With Dermatology Life Quality Index Score of 0 or 1 | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100. | baseline, weeks 4, 8, 12, 16, 28, 40, 52, 64 |
| Proportion of Subjects With Dermatology Life Quality Index Score ≤ 5 | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100. | Baseline, weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Proportion of Subjects With a Reduction of ≥ 5 Points in Dermatology Life Quality Index From Baseline | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100 | baseline, weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Changes From Baseline in Percent Affected Body Surface Area | The percent BSA affected with psoriasis will be estimated at each study visit. The investigator may use the estimate that 1% BSA is equivalent to the area of the subject's closed hand (palm with fingers held together). | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Change From Baseline in Static Physician's Global Assessment | The sPGA is used to determine the overall severity of psoriasis lesions at a given time point. Its score ranges from 0 to 5 with higher scores indicating greater severity. | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Changes From Baseline Body Surface Area x Physician's Global Assessment Over Time | The metric of BSA x sPGA is a multiplication of the percentage BSA covered and the sPGA score. The scale range for the sPGA is 0 to 5. The scale range for BSA in this study was >=3% (inclusion criterion), which means that it has to be at least 3%, and it can be as high as 100% hypothetically. So the minimum score for sPGA x BSA = 0, and the maximum score is 5 x 100 = 500. So the range for sPGA x BSA in this study was 0 to 500. The BSA has a range of 0% to 100% where higher percentages indicate a worse outcome or worse disease The sPGA has a range of 0 (clear) to 5 (severe) where higher values indicate a worse outcome or worse disease. sPGA is used to determine the overall severity of psoriasis lesions at a given time point. Its score ranges from 0 to 5. BSA covered is reported as percent of body surface area covered. Total score for BSA x sPGA ranges from 0 to 500 with higher scores indicating greater severity. | weeks 4, 8, 12, 16, 28, 40, 52, 64 |
| Changes From Baseline Psoriasis Area Severity Index (% of Psoriasis Area Severity Index Improvement From Baseline, Absolute Psoriasis Area Severity Index ) Over Time | The PASI is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI analyzes the four regions of the body (head, trunk, upper and lower limbs). It ranges from 0 to 72 with higher scores indicating greater severity. | baseline, weeks 4,16, 28 and 52 |
| Change From Baseline in Itch-Numeric Rating Scale | The Itch-Numerical Rating Scale (I-NRS) is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no itch and score of 10 indicates indicates worst imaginable itch | baseline, weeks 4, 8, 12, 16, 28, 40, 52, 64 |
| Change From Baseline in Scaling-Numeric Rating Scale | The Scaling-NRS (S-NRS) is a simple, 11-point self-administered numeric rating scale that is administered at each visit. A score of 0 represents 'no scaling' and a score of 10, indicates 'worst scaling imaginable'. | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Change From Baseline in Pain-Numeric Rating Scale | The P-NRS is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no pain. A score of 10 indicates worst pain imaginable | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Proportion of Patients With Itch Score of 0 | The Itch-Numerical Rating Scale (I-NRS) is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no itch and score of 10 indicates indicates worst imaginable itch. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100 | weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Proportion of Patients With Scaling Score of 0 | The Scaling-NRS (S-NRS) is a simple, 11-point self-administered numeric rating scale that is administered at each visit. A score of 0 represents 'no scaling' and a score of 10, indicates 'worst scaling imaginable'. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100 | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Proportion of Patients With Pain Score of 0 | The P-NRS is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no pain. A score of 10 indicates worst pain imaginable. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100. | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
| Improvement From Baseline in Work Productivity Measured by Change in Work Productivity and Activity Impairment Scale Over Time | The WPAI is a validated, subject-reported quantitative assessment of the amount of absenteeism, presenteeism and daily activity impairment attributable to general health or a specific health problem. WPAI surveys were analyzed based on published algorithms to determine the following: current employment status, absenteeism, presenteeism, total activity impairment , and total work productivity impairment. Each WPAI score is expressed as impairment percentages (0-100), with higher scores indicating greater impairment (worse outcomes). | baseline, weeks 16, 28, 40, 52, 64 |
| Assessment of Patient Satisfaction With Treatment Measured by Change From Baseline in Treatment Satisfaction Questionnaire for Medication Over Time | The TSQM is a general measure of treatment satisfaction with medication, suitable for use across a wide variety of medication types and illness conditions. The 14-item TSQM Version 1.4 is a reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. The TSQM domain scores range from 0-100 with higher scores representing higher satisfaction on that domain | baseline, weeks 4, 8, 12, 16, 28, 40, 52, 64 |
| Assessment of Tildrakizumab Overall Satisfaction Over Time Using Numerical Rating Scales | The Tildrakizumab Overall Satisfaction Scale is an 11-point simple, self-administered numeric rating scale. Subjects indicate their overall satisfaction by circling the integer that best describes their experience on a scale. A score of 0 indicates 'not satisfied' and 10 indicates 'extremely satisfied'. | weeks 4, 8, 12, 16, 28, 40, 52, 64 |
| Assessment of Patient Happiness With Psoriasis Control Over Time Using Numerical Rating Scale | The Patient Happiness with Psoriasis Control assessment is an 11-point simple, self- administered numeric rating scale ranging in score from 0 to 10 that is administered at each visit. Subjects indicate their overall happiness with psoriasis control by circling the integer that best describes their experience on a scale. A score of 0 indicates 'extremely unhappy'. A score of 10 indicates 'extremely happy'. | weeks 4, 8, 12, 16, 28, 40, 52, 64 |
| Grandville |
| Michigan |
| 49418 |
| United States |
| Lost to Follow-up |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| ID |
|---|
| Title |
|---|
| Description |
|---|
| OG000 | Tildrakizumab 100 mg | Injections of tildrakizumab: given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52 |
|
|
|
| Secondary | Improvement in Quality of Life Measured by Change From Baseline in Psychological General Well-Being Scale Over Time | The Psychological General Well-Being scale is a self-administered validated psychometric instrument that measures a person's emotional well-being. It is specifically designed to be suitable for assessing psychological well being in the general medical population as opposed to a psychiatric population. The 22 questions of the PGWB can be further divided into 6 domains: anxiety, depressed mood, positive well being, self-control, general health, and vitality. The PGWB is graded on a Likert scale, which is commonly used in psychometric questionnaires where the answers range from strongly agree to strongly disagree with gradations in between. Total scores range from 0 to 110, with higher scores indicating better psychological well being. This instrument has been validated and used in many countries on large samples of the general population and on various subsets of medical patients. The values reported are change in score from baseline. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | baseline, weeks 4, 8, 12, 16, 40, 64 |
|
|
|
|
| Secondary | Improvement in Quality of Life Measured by Change From Baseline in Dermatology Life Quality Index Over Time | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life | Posted | Mean | Standard Deviation | score on a scale | week 64 |
|
|
|
|
| Secondary | Proportion of Subjects With Dermatology Life Quality Index Score of 0 or 1 | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100. | The intent-to-treat (ITT) population | Posted | Number | Percentage of subjects | baseline, weeks 4, 8, 12, 16, 28, 40, 52, 64 |
|
|
|
|
| Secondary | Proportion of Subjects With Dermatology Life Quality Index Score ≤ 5 | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100. | The intent-to-treat (ITT) population | Posted | Number | Percentage of subjects | Baseline, weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Proportion of Subjects With a Reduction of ≥ 5 Points in Dermatology Life Quality Index From Baseline | The DLQI is a self-administered and user-friendly validated questionnaire used to measure the health-related quality of life of adult patients suffering from a skin disease. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. Higher scores mean greater impairment of patient's QoL. The DLQI or Dermatology Life Quality Index measures patient's quality of life. The score ranges from 0 to 30. Lower scores indicate less impairment in quality of life. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100 | The intent-to-treat (ITT) population | Posted | Number | Percentage of subjects | baseline, weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Changes From Baseline in Percent Affected Body Surface Area | The percent BSA affected with psoriasis will be estimated at each study visit. The investigator may use the estimate that 1% BSA is equivalent to the area of the subject's closed hand (palm with fingers held together). | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | Percent BSA | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Change From Baseline in Static Physician's Global Assessment | The sPGA is used to determine the overall severity of psoriasis lesions at a given time point. Its score ranges from 0 to 5 with higher scores indicating greater severity. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Changes From Baseline Body Surface Area x Physician's Global Assessment Over Time | The metric of BSA x sPGA is a multiplication of the percentage BSA covered and the sPGA score. The scale range for the sPGA is 0 to 5. The scale range for BSA in this study was >=3% (inclusion criterion), which means that it has to be at least 3%, and it can be as high as 100% hypothetically. So the minimum score for sPGA x BSA = 0, and the maximum score is 5 x 100 = 500. So the range for sPGA x BSA in this study was 0 to 500. The BSA has a range of 0% to 100% where higher percentages indicate a worse outcome or worse disease The sPGA has a range of 0 (clear) to 5 (severe) where higher values indicate a worse outcome or worse disease. sPGA is used to determine the overall severity of psoriasis lesions at a given time point. Its score ranges from 0 to 5. BSA covered is reported as percent of body surface area covered. Total score for BSA x sPGA ranges from 0 to 500 with higher scores indicating greater severity. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | weeks 4, 8, 12, 16, 28, 40, 52, 64 |
|
|
|
|
| Secondary | Changes From Baseline Psoriasis Area Severity Index (% of Psoriasis Area Severity Index Improvement From Baseline, Absolute Psoriasis Area Severity Index ) Over Time | The PASI is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI analyzes the four regions of the body (head, trunk, upper and lower limbs). It ranges from 0 to 72 with higher scores indicating greater severity. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | baseline, weeks 4,16, 28 and 52 |
|
|
|
|
| Secondary | Change From Baseline in Itch-Numeric Rating Scale | The Itch-Numerical Rating Scale (I-NRS) is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no itch and score of 10 indicates indicates worst imaginable itch | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | baseline, weeks 4, 8, 12, 16, 28, 40, 52, 64 |
|
|
|
|
| Secondary | Change From Baseline in Scaling-Numeric Rating Scale | The Scaling-NRS (S-NRS) is a simple, 11-point self-administered numeric rating scale that is administered at each visit. A score of 0 represents 'no scaling' and a score of 10, indicates 'worst scaling imaginable'. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Change From Baseline in Pain-Numeric Rating Scale | The P-NRS is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no pain. A score of 10 indicates worst pain imaginable | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Proportion of Patients With Itch Score of 0 | The Itch-Numerical Rating Scale (I-NRS) is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no itch and score of 10 indicates indicates worst imaginable itch. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100 | The intent-to-treat (ITT) population | Posted | Number | Percentage of participants | weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Proportion of Patients With Scaling Score of 0 | The Scaling-NRS (S-NRS) is a simple, 11-point self-administered numeric rating scale that is administered at each visit. A score of 0 represents 'no scaling' and a score of 10, indicates 'worst scaling imaginable'. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100 | The intent-to-treat (ITT) population | Posted | Number | percentage of participants | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Proportion of Patients With Pain Score of 0 | The P-NRS is a simple, 11-point self-administered numeric rating scale. A score of 0 indicates no pain. A score of 10 indicates worst pain imaginable. For 'Units of Measure'- Data entered is percentage of participants, which is calculated by multiplying the value obtained (Proportion in this case) by 100. | The intent-to-treat (ITT) population | Posted | Number | Percentage of participants | Weeks 4, 8, 12, 16, 28, 40, 52, and 64 |
|
|
|
|
| Secondary | Improvement From Baseline in Work Productivity Measured by Change in Work Productivity and Activity Impairment Scale Over Time | The WPAI is a validated, subject-reported quantitative assessment of the amount of absenteeism, presenteeism and daily activity impairment attributable to general health or a specific health problem. WPAI surveys were analyzed based on published algorithms to determine the following: current employment status, absenteeism, presenteeism, total activity impairment , and total work productivity impairment. Each WPAI score is expressed as impairment percentages (0-100), with higher scores indicating greater impairment (worse outcomes). | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | baseline, weeks 16, 28, 40, 52, 64 |
|
|
|
|
| Secondary | Assessment of Patient Satisfaction With Treatment Measured by Change From Baseline in Treatment Satisfaction Questionnaire for Medication Over Time | The TSQM is a general measure of treatment satisfaction with medication, suitable for use across a wide variety of medication types and illness conditions. The 14-item TSQM Version 1.4 is a reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. The TSQM domain scores range from 0-100 with higher scores representing higher satisfaction on that domain | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | baseline, weeks 4, 8, 12, 16, 28, 40, 52, 64 |
|
|
|
|
| Secondary | Assessment of Tildrakizumab Overall Satisfaction Over Time Using Numerical Rating Scales | The Tildrakizumab Overall Satisfaction Scale is an 11-point simple, self-administered numeric rating scale. Subjects indicate their overall satisfaction by circling the integer that best describes their experience on a scale. A score of 0 indicates 'not satisfied' and 10 indicates 'extremely satisfied'. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | weeks 4, 8, 12, 16, 28, 40, 52, 64 |
|
|
|
|
| Secondary | Assessment of Patient Happiness With Psoriasis Control Over Time Using Numerical Rating Scale | The Patient Happiness with Psoriasis Control assessment is an 11-point simple, self- administered numeric rating scale ranging in score from 0 to 10 that is administered at each visit. Subjects indicate their overall happiness with psoriasis control by circling the integer that best describes their experience on a scale. A score of 0 indicates 'extremely unhappy'. A score of 10 indicates 'extremely happy'. | The intent-to-treat (ITT) population | Posted | Mean | Standard Deviation | score on a scale | weeks 4, 8, 12, 16, 28, 40, 52, 64 |
|
|
|
|
| Other Pre-specified | Treatment-emergent AEs | The reported values are entered in the 'Other Adverse events' section | Not Posted | baseline, weeks 4, 8, 12, 16, 28, 40, 52,,64 | Participants |
| 0 |
| 55 |
| 4 |
| 55 |
| 29 |
| 55 |
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| Ischaemic stroke | Nervous system disorders | Systematic Assessment |
|
| IgA nephropathy | Renal and urinary disorders | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
|
| Large intestine polyp | Gastrointestinal disorders | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Skin papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| Haematuria | Renal and urinary disorders | Systematic Assessment |
|
| Dermatitis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Eczema | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Psoriasis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Hypertension | Vascular disorders | Systematic Assessment |
|
Not provided
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 40 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 60 |
|
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 52 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|
|
| Week 28 (Total Activity Impairment) |
|
|
| Week 40 (Total Activity Impairment) |
|
|
| Week 52 (Total Activity Impairment) |
|
|
| Week 64 Total Activity Impairment) |
|
|
| Baseline (Total Work Productivity Impairment) |
|
|
| Week 16 (Total Work Productivity Impairment) |
|
|
| Week 28 (Total Work Productivity Impairment) |
|
|
| Week 40 (Total Work Productivity Impairment) |
|
|
| Week 52 (Total Work Productivity Impairment) |
|
|
| Week 64 (Total Work Productivity Impairment) |
|
|
| Baseline (Absenteeism) |
|
|
| Week 16 (Absenteeism) |
|
|
| Week 28 (Absenteeism) |
|
|
| Week 40 (Absenteeism) |
|
|
| Week 52 (Absenteeism) |
|
|
| Week 64 (Absenteeism) |
|
|
| Baseline (Presenteeism) |
|
|
| Week 16 (Presenteeism) |
|
|
| Week 28 (Presenteeism) |
|
|
| Week 40 (Presenteeism) |
|
|
| Week 52 (Presenteeism) |
|
|
| Week 64 (Presenteeism) |
|
|
| <0.001 |
| Superiority |
|
| Week 12 (Effectiveness) |
|
|
| Week 16 (Effectiveness) |
|
|
| Week 28 (Effectiveness) |
|
|
| Week 40 (Effectiveness) |
|
|
| Week 52 (Effectiveness) |
|
|
| Week 64 (Effectiveness) |
|
|
| Week 4 (Convenience) |
|
|
| Week 8 (Convenience) |
|
|
| Week 12 (Convenience) |
|
|
| Week 16 (Convenience) |
|
|
| Week 28 (Convenience) |
|
|
| Week 40 (Convenience) |
|
|
| Week 52 (Convenience) |
|
|
| Week 64 (Convenience) |
|
|
| Week 4 (Global Satisfaction) |
|
|
| Week 8 (Global Satisfaction) |
|
|
| Week 12 (Global Satisfaction) |
|
|
| Week 16 (Global Satisfaction) |
|
|
| Week 28 (Global Satisfaction) |
|
|
| Week 40 (Global Satisfaction) |
|
|
| Week 52 (Global Satisfaction) |
|
|
| Week 64 (Global Satisfaction) |
|
|
| Week 4 (Side Effects) |
|
|
| Week 8 (Side Effects) |
|
|
| Week 12 (Side Effects) |
|
|
| Week 16 (Side Effects) |
|
|
| Week 28 (Side Effects) |
|
|
| Week 40 (Side Effects) |
|
|
| Week 52 (Side Effects) |
|
|
| Week 64 (Side Effects) |
|
|
| Exact binomial test |
| <0.001 |
| Superiority |
| Treatment Satisfaction Questionnaire for Medication over time - Convenience | Mean | 82.2 | Standard Deviation | 16.35 | 2-Sided | Superiority |
| Treatment Satisfaction Questionnaire for Medication over time - Global Satisfaction | Mean | 81.9 | Standard Deviation | 20.47 | 2-Sided | Superiority |
|
| Week 12 (Improvement in Symptoms) |
|
|
| Week 16 (Improvement in Symptoms) |
|
|
| Week 28 (Improvement in Symptoms) |
|
|
| Week 40 (Improvement in Symptoms) |
|
|
| Week 52 (Improvement in Symptoms) |
|
|
| Week 64 (Improvement in Symptoms) |
|
|
| Week 4 (Speed of Symptom Improvement) |
|
|
| Week 8 (Speed of Symptom Improvement) |
|
|
| Week 12 (Speed of Symptom Improvement) |
|
|
| Week 16 (Speed of Symptom Improvement) |
|
|
| Week 28 (Speed of Symptom Improvement) |
|
|
| Week 40 (Speed of Symptom Improvement) |
|
|
| Week 52 (Speed of Symptom Improvement) |
|
|
| Week 64 (Speed of Symptom Improvement) |
|
|
| Week 4 (Frequency of Taking Medication) |
|
|
| Week 8 (Frequency of Taking Medication) |
|
|
| Week 12 (Frequency of Taking Medication) |
|
|
| Week 16 (Frequency of Taking Medication) |
|
|
| Week 28 (Frequency of Taking Medication) |
|
|
| Week 40 (Frequency of Taking Medication) |
|
|
| Week 52 (Frequency of Taking Medication) |
|
|
| Week 64 (Frequency of Taking Medication) |
|
|
| Week 4 (Side Effects) |
|
|
| Week 8 (Side Effects) |
|
|
| Week 12 (Side Effects) |
|
|
| Week 16 (Side Effects) |
|
|
| Week 28 (Side Effects) |
|
|
| Week 40 (Side Effects) |
|
|
| Week 52 (Side Effects) |
|
|
| Week 64 (Side Effects) |
|
|
| Mean |
| 8.3 |
| Standard Deviation |
| 2.30 |
| 2-Sided |
| Superiority |
| Frequency of Taking Medication | Mean | 9.1 | Standard Deviation | 1.70 | 2-Sided | Superiority |
| Side Effects | Mean | 9.6 | Standard Deviation | 0.68 | 2-Sided | Superiority |
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 28 |
|
|
| Week 40 |
|
|
| Week 52 |
|
|
| Week 64 |
|
|